Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (SLNO) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Soleno Therapeutics, Inc. (SLNO), covering cash flow, earnings, and balance sheets.
Soleno Therapeutics, Inc. (SLNO) Income Statement & Financial Overview
Analyze Soleno Therapeutics, Inc.’s SLNO earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $494000.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$494000.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $13.52M | $21.49M | $30.14M | $12.34M |
| SG&A Expenses | $29.26M | $37.30M | $49.20M | $10.39M |
| Operating Expenses | $45.74M | $59.12M | $80.21M | $22.74M |
| Total Costs & Expenses | $0.00 | $60.27M | $80.21M | $23.23M |
| Interest Income | $0.00 | $3.37M | $3.60M | $3.01M |
| Interest Expense | -$1.36M | $231000.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $503000.00 | $500000.00 | $494000.00 |
| EBITDA | $0.00 | -$55.25M | -$78.83M | -$22.74M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | -$59.12M | -$80.21M | -$23.23M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $0.00 | $3.13M | $3.60M | $1.38M |
| Income Before Tax | -$43.77M | -$55.98M | -$76.62M | -$21.85M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$43.77M | -$55.98M | -$76.62M | -$21.85M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.95 | -$1.27 | -$1.83 | -$0.57 |
| Diluted EPS | -$0.95 | -$1.27 | -$1.83 | -$0.57 |
| Weighted Avg Shares Outstanding | $46.18M | $43.92M | $41.88M | $38.63M |
| Weighted Avg Shares Outstanding (Diluted) | $46.18M | $43.92M | $41.88M | $38.63M |
Financial performance has remained strong, with revenue growing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached $0.00 in Q1 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $0.00. Net income rose to -$43.77M, keeping EPS at -$0.95. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan